Studie zkoumající bezpečnost a účinnost krému Tapinarof, 1 % u účastníků ve věku od 3 měsíců do < 24 měsíců s atopickou dermatitidou (Adoring)
Randomizovaná, dvojitě zaslepená, kontrolovaná vozidlem (období 1) a otevřená (období 2) studie fáze 3, která zkoumá bezpečnost a účinnost krému Tapinarof, 1 %, u pediatrických účastníků ve věku 3 měsíců až < 24 měsíců s atopickou dermatitidou
The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní místa
-
-
Alberta
-
Calgary, Alberta, Kanada, T2J 7E1
- Dermatology Research Institute
-
Red Deer, Alberta, Kanada, T4P 1K4
- CARe Clinic (Central Alberta Research Clinic)
-
-
British Columbia
-
Surrey, British Columbia, Kanada, V3R 6A7
- Dr. Chih-Ho Hong Medical Inc.
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3J 0S9
- Manitoba Allergy Research Inc.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 5R3
- Maritime Dermatology
-
-
Ontario
-
Burlington, Ontario, Kanada, L7L 6W6
- Halton Pediatric Allergy
-
Hamilton, Ontario, Kanada, L8S 1G5
- Triple A Lab Inc.
-
Niagara Falls, Ontario, Kanada, L2H 1C4
- Allergy Research Canada Inc.
-
-
Saskatchewan
-
Regina, Saskatchewan, Kanada, S4V 1R9
- Dr. Rachel Asiniwasis Medical Professional Corporation
-
Saskatoon, Saskatchewan, Kanada, S7K 2C1
- Skinsense Medical Research
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35209
- AllerVie Clinical Research
-
-
Arkansas
-
Bryant, Arkansas, Spojené státy, 72022
- Dermatology Trial Associates
-
-
California
-
Los Angeles, California, Spojené státy, 90045
- Dermatology Research Associates
-
Sacramento, California, Spojené státy, 95815
- Integrative Skin Science and Research
-
San Diego, California, Spojené státy, 92123
- Allergy and Asthma Medical Group and Research Center
-
Thousand Oaks, California, Spojené státy, 91320
- Clinical Trials Research Institute
-
-
Colorado
-
Castle Rock, Colorado, Spojené státy, 80109
- Clarity Dermatology
-
-
Florida
-
Boca Raton, Florida, Spojené státy, 33486
- Skin Care Research, LLC.
-
Jacksonville, Florida, Spojené státy, 32256
- APEX Clinical Trials
-
Wellington, Florida, Spojené státy, 33449
- TruDerm Research
-
-
Georgia
-
Cumming, Georgia, Spojené státy, 30040
- Cleaver Medical Group Dermatology, Inc
-
-
Idaho
-
Meridian, Idaho, Spojené státy, 83646
- Ada West Research
-
-
Illinois
-
Skokie, Illinois, Spojené státy, 60077
- Endeavor Health Clinical Trials Center
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46250
- Dawes Fretzin Clinical Research Group, LLC
-
Plainfield, Indiana, Spojené státy, 46168
- The Indiana Clinical Trials Center, PC
-
-
Kentucky
-
Bowling Green, Kentucky, Spojené státy, 42104
- Equity Medical, LLC
-
-
Maryland
-
Rockville, Maryland, Spojené státy, 20850
- Lawrence J Green, MD LLC
-
-
Michigan
-
Auburn Hills, Michigan, Spojené státy, 48326
- Oakland Hills Dermatology
-
-
Minnesota
-
New Brighton, Minnesota, Spojené státy, 55112
- Minnesota Clinical Study Center
-
-
Mississippi
-
Ridgeland, Mississippi, Spojené státy, 39157
- SKY Integrative Medical Center
-
-
Missouri
-
Saint Joseph, Missouri, Spojené státy, 64506
- MediSearch Clinical Trials
-
-
Nevada
-
Reno, Nevada, Spojené státy, 89509
- Skin Cancer and Dermatology Institute
-
-
New York
-
Kew Gardens, New York, Spojené státy, 11415
- Forest Hills Dermatology Group
-
New York, New York, Spojené státy, 10012
- Bobby Buka MD, PC
-
The Bronx, New York, Spojené státy, 10455
- Equity Medical, LLC
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27516
- The University of North Carolina Dermatology and Skin Cancer Center
-
-
Ohio
-
Fairborn, Ohio, Spojené státy, 45324
- Dermatologists of Central States, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73120
- Allergy Asthma and Clinical Research Center
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97210
- Oregon Dermatology and Research Center
-
Portland, Oregon, Spojené státy, 97239
- Oregon Health & Science University
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
North Charleston, South Carolina, Spojené státy, 29420
- National Allergy and Asthma Research, LLC.
-
-
Texas
-
Bellaire, Texas, Spojené státy, 77401
- The University of Texas Health Science Center at Houston
-
Dallas, Texas, Spojené státy, 75230
- Dermatology Treatment and Research Center
-
Southlake, Texas, Spojené státy, 76092
- Stryde Research - Epiphany Dermatology
-
-
Washington
-
Spokane, Washington, Spojené státy, 99202
- Dermatology Specialists of Spokane
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Infants and toddlers born at term (≥37 weeks of gestational age) that are 3 months to <24 months of age at the Screening visit.
- Clinical diagnosis of atopic dermatitis (AD), AD covering >5% Body Surface Area (BSA) and validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 2, 3 or 4
- Legal guardian or primary caregiver is willing and able to sign informed consent form before any study-related activities
- Legal guardian or primary caregiver is able and willing to adhere to protocol requirements
Exclusion Criteria:
- Significant neurological disorder or history of seizure
- Know clinically significant cardiac rhythm or cardiac disorder
- History of sudden infant death in a sibling
- Clinically significant chromosome abnormality
- History of or ongoing serious illness or medical, physical or psychiatric condition(s) that may interfere with the participant's participation
- Diseases that could cause pruritic and/or sleep disruption
- Immunocompromised
- Current chronic or acute infection requiring treatment
- Use of prohibited medication(s) or procedure(s)
- Use of prohibited medications by breastfeeding mother if breastfeeding participant
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Tapinarof cream
Tapinarof cream, 1%, applied topically once daily |
Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.
Ostatní jména:
|
|
Komparátor placeba: Vehicle cream
Vehicle cream is applied topically once daily for up to 8-weeks. |
Applied topically once daily to lesions on participant's skin during the Double-Blind period. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of participants who have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement from Baseline to Week 8
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants who enter with or achieve have a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of clear or almost clear (0 or 1) and a minimum 2-grade Improvement at least once during the Open-Label Period
Časové okno: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
The vIGA-AD is a clinical tool for assessing the current state/severity of a subject's atopic dermatitis at a given timepoint.. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is reported as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of participants with ≥ 75% improvement in Eczema Area and Severity Index (EASI) Score from Baseline to Week 8.
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the %BSA affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the %BSA involved for each body region relative to the whole body. The subject's scalp is excluded from this assessment. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Mean change in percentage of total body surface area (%BSA) affected from Baseline to Week 8
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Assessment of %BSA is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% [10 handprints], upper extremities = 20% [20 handprints], trunk (including axillae and groin) = 30% [30 handprints], lower extremities, including buttocks, = 40% [40 handprints]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Percentage of participants with ≥ 90% improvement in Eczema Area and Severity Index (EASI) score from Baseline to Week 8
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
Severity Index (EASI) score from Baseline to Week 8 Description: The EASI is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks.
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Number of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Časové okno: Baseline to the end of the Open-Label Period, up to 56 weeks
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks .
|
|
Percentage of participants with one or more Treatment Emergent Adverse Events (TEAEs)
Časové okno: Baseline to the end of the Open-Label Period, up to 56 weeks.
|
TEAEs are AEs that started on or after the first dose of study medication. |
Baseline to the end of the Open-Label Period, up to 56 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (overall)
Časové okno: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Časové okno: Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Baseline to last planned visit in the Double-Blind Period, up to 8 weeks
|
|
Investigator-assessed Local Tolerability Scale (LTS) scores by visit (sensitive areas)
Časové okno: Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
The LTS measures the presence and overall degree of irritation at the application site(s) using a 5-point scale, where 0 indicates no irritation and 4 very severe irritation. |
Beginning of Open-Label to the end of the Open-Label Period, up to 48 weeks.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Ředitel studie: Clinical Lead Late-Stage Clinical Development, Organon and Co
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Genetické choroby, vrozené
- Onemocnění imunitního systému
- Přecitlivělost, okamžitá
- Přecitlivělost
- Kožní choroby
- Kožní onemocnění, genetické
- Kožní onemocnění, ekzematózní
- Dermatitida
- Vrozené, dědičné a neonatální nemoci a abnormality
- Onemocnění kůže a pojivové tkáně
- Dermatitida, atopika
- Ekzém
- tapinarof
Další identifikační čísla studie
Další identifikační čísla studie
- OG0505-3104
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .